close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nucleix

News headline image
A Study Published in European Urology Oncology Demonstrated Bladder EpiCheck® Can Detect High-Grade Bladder Cancer Recurrences Missed by White Light Cystoscopy
From Nucleix
Via Business Wire
News headline image
Nucleix to Present Data Showcasing Performance and Clinical Utility of Bladder EpiCheck® Monitoring in Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence at AUA 2025
From Nucleix
Via Business Wire
News headline image
NHS Lothian and Nucleix Presented Data at EAU25 Showcasing Potential of Bladder EpiCheck® to Improve Detection of Disease Recurrence in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients
From Nucleix
Via Business Wire
News headline image
A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in Europe
From Nucleix
Via Business Wire
News headline image
Results from Pivotal Clinical Study Demonstrate Potential of Nucleix’s Bladder EpiCheck® to Improve Disease Recurrence Detection in Non-Muscle Invasive Bladder Cancer (NMIBC) Surveillance
From Nucleix
Via Business Wire
News headline image
Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes
From Nucleix
Via Business Wire
News headline image
Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands
From Nucleix
Via Business Wire
News headline image
Nucleix Bladder EpiCheck® Now Available in France via the Association Francaise d'Urologie (AFU) Registry for Surveillance of Recurrence of Bladder Cancer
From Nucleix
Via Business Wire
News headline image
Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting
From Nucleix
Via Business Wire
News headline image
Nucleix Appoints Michael G. Vicari as Chief Commercial Officer
From Nucleix
Via Business Wire
News headline image
Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence
From Nucleix
Via Business Wire
News headline image
Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting
From Nucleix
Via Business Wire
News headline image
Nucleix Receives CAP Accreditation and CLIA Certification for its San Diego Clinical Laboratory
From Nucleix
Via Business Wire
News headline image
Nucleix Expands EU Label Indication of Bladder EpiCheck® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer
From Nucleix
Via Business Wire
News headline image
Bladder EpiCheck® Included in 2022 European Association of Urology (EAU) Clinical Guidelines on Non-Muscle Invasive Bladder Cancer (NMIBC)
From Nucleix
Via Business Wire
News headline image
Nucleix Announces Recent Advancements in Early Lung Cancer Detection Program
From Nucleix
Via Business Wire
News headline image
Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
From Nucleix
Via Business Wire
News headline image
Alternating Nucleix’s Bladder EpiCheck® With Standard Surveillance Can Reduce Burden on Patients and Healthcare Systems
From Nucleix
Via Business Wire
News headline image
Nucleix Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients
From Nucleix
Via Business Wire
News headline image
Nucleix Secures $55 Million Funding Led by RA Capital Management and Additional Prominent Life Science Investors to Advance Lung EpiCheck® for Early Detection of Lung Cancer
From Nucleix
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today